#### **Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors**

Zhi Xu<sup>1#</sup>, Xinying Huo<sup>1#</sup>, Chuanning Tang<sup>2</sup>, Hua Ye<sup>2</sup>, Vijayalakshmi Nandakumar<sup>3</sup>, Feng

Lou<sup>2</sup>, Dandan Zhang<sup>2</sup>, Shouwen Jiang<sup>2</sup>, Hong Sun<sup>2</sup>, Haichao Dong<sup>2</sup>, Guangchun Zhang<sup>2</sup>,

Zhiyuan Liu<sup>2</sup>, Zhishou Dong<sup>2</sup>, Baishuai Guo<sup>2</sup>, He Yan<sup>2</sup>, Chaowei Yan<sup>2</sup>, Lu Wang<sup>2</sup>,

Ziyi Su<sup>2</sup>, Yangyang Li<sup>2</sup>, Dongying Gu<sup>1</sup>, Xiaojing Zhang<sup>1</sup>, Xiaomin Wu<sup>1</sup>,

Xiaowei Wei<sup>1</sup>, Lingzhi Hong<sup>1</sup>, Yangmei Zhang<sup>1</sup>, Jinsong Yang<sup>1</sup>, Yonglin Gong<sup>1</sup>, Cuiju Tang<sup>1</sup>, Lindsey Jones<sup>3</sup>, Xue F Huang<sup>3</sup>, Si-Yi Chen<sup>3</sup>\*, Jinfei Chen<sup>1</sup>\*

> <sup>1</sup>Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.

<sup>2</sup>San Valley Biotechnology Inc., Beijing 100044, China

<sup>3</sup>Norris Comprehensive Cancer Center,

Department of Molecular Microbiology and Immunology, Keck School of Medicine,

University of Southern California, Los Angeles, CA 90033, USA.

<sup>#</sup>These two authors contributed equally.

\*Corresponding Authors:

Jinfei Chen, MD, Department of Oncology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, P. R. China; Fax: +86 25 87726234; Tel: +86 25 87726242; Email: jinfeichen@sohu.com.

Dr. Si-Yi Chen, MD., Ph.D., Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. E-mail: siyichen@usc.edu; Tel: 323 442 7727; Fax: 323 442 7729.

### **Supplemental Figure Legend**

**Supplementary Fig. 1**. Filter process of variants. Note: (a) Strand-biased variants were eliminated using Integrative Genomics Viewer (IGV) software (http://www.broadinstitute.org/igv); (b) Variants in AMPL339432 should be eliminated, because this amplicon is not uniquely matched to PIK3CA in the human genome; (c) All of our statistical analysis was based on the data in blue box (Missense and in/del mutations).

**Supplementary Fig. 2**. Sequence read distribution across 189 amplicons generated from 121 FFPE specimens, normalized to 300,000 reads per sample.

A. Distribution of average coverage of each amplicon. Data are showed as mean  $\pm$ SD.

B. Number of amplicons with a given read depth, sorted in bins of 100 reads. (blue bars represent number of target amplicons within read depth, red line represents % of target amplicons  $\geq$  read depth).

**Supplementary Table 1**. Mutations (including Missense point mutations/deletion/insertion) frequencies in 45 genes (737 loci) in gastric and intestinal GISTs.

**Supplementary Table 2**. Frequencies of point mutations, insertion, and deletion mutations in 737 loci of 45 genes in 121 GISTs.

**Supplementary Table 3**. Validation by Sanger sequencing **Supplementary Table 4**. Patients' characteristics for 121 GIST samples

## Supplementary Fig.1. Filter process of variants



## Supplementary Figure2



В



Supplementary Table 1. Mutations (including Missense point mutations/deletion/insertion) frequencies in 45 genes (737 loci) in gastric and intestinal GISTs.

Genes	Number of samples with mutations (Mutation frequency in 121 samples)	Number of gastric samples with mutations (Mutation frequency in 76 gastric samples)	Number of intestinal samples with mutations (Mutation frequency in 45 intestinal samples)
ABL1	0(0.0%)	0(0.0%)	0(0.0%)
AKT1	0(0.0%)	0(0.0%)	0(0.0%)
ALK	0(0.0%)	0(0.0%)	0(0.0%)
APC	0(0.0%)	0(0.0%)	0(0.0%)
ATM	0(0.0%)	0(0.0%)	0(0.0%)
BRAF	1(0.8%)	1(1.3%)	0(0.0%)
CDH1	1(0.8%)	0(0.0%)	1(2.2%)
CDKN2A	0(0.0%)	0(0.0%)	0(0.0%)
CSF1R	0(0.0%)	0(0.0%)	0(0.0%)
CTNNB1	0(0.0%)	0(0.0%)	0(0.0%)
EGFR	1(0.8%)	0(0.0%)	1(2.2%)
ERBB2	0(0.0%)	0(0.0%)	0(0.0%)
ERBB4	1(0.8%)	1(1.3%)	0(0.0%)
FBXW7	0(0.0%)	0(0.0%)	0(0.0%)
FGFR1	0(0.0%)	0(0.0%)	0(0.0%)
FGFR2	0(0.0%)	0(0.0%)	0(0.0%)
FGFR3	0(0.0%)	0(0.0%)	0(0.0%)
FLT3	3(2.5%)	3(3.9%)	0(0.0%)
GNAS	0(0.0%)	0(0.0%)	0(0.0%)
HNF1A	0(0.0%)	0(0.0%)	0(0.0%)
HRAS	0(0.0%)	0(0.0%)	0(0.0%)
IDH1	0(0.0%)	0(0.0%)	0(0.0%)
JAK3	0(0.0%)	0(0.0%)	0(0.0%)
KDR	0(0.0%)	0(0.0%)	0(0.0%)
КІТ	60(49.6%)	41(53.9%)	19(42.2%)
KRAS	1(0.8%)	1(1.3%)	0(0.0%)
MET	0(0.0%)	0(0.0%)	0(0.0%)
MLH1	0(0.0%)	0(0.0%)	0(0.0%)
MPL	0(0.0%)	0(0.0%)	0(0.0%)
NOTCH1	0(0.0%)	0(0,0%)	0(0.0%)
NPM1	0(0.0%)	0(0,0%)	0(0.0%)
NRAS	0(0.0%)	0(0,0%)	0(0.0%)
PDGFRA	1(0.8%)	1(1 3%)	0(0.0%)
PIK3CA	0(0.0%)	0(0.0%)	0(0.0%)
PTFN	1(0.8%)	0(0.0%)	1(2.2%)
PTPN11	1(0.0%) 0(0.0%)	0(0.0%)	0(0.0%)
RB1	0(0.0%)	0(0.0%)	0(0.0%)
RFT	0(0.0%)	0(0.0%)	0(0.0%)
SMAD4	0(0.0%)	0(0.0%)	0(0.0%)
	0(0.0%)	0(0.0%)	
SMARCDI		0(0.0%)	
SINC	0(0.0%)	0(0.0%)	
	0(0.0%) 1(0.0%)	0(0.0%) 1(1.20/)	
11.72	T(0.0%)	I(I.3%)	0(0.0%)

Gene Mutations	Number of samples with this mutation site	Number of samples with this mutation gene	Mutation Frequency	Gene mutation frequency in publications	Site mutation frequency in gene in publications	If reported in GIST in COSMIC database	If reported in GIST in MyCancerGenom
BRAFc.1799T>A	1	1	0.8%	<1% (mycancergenome)	-	YES	YES
KITc.1667_1672del6;c.1669_1674del6	7					YES	NO
KITc.1679T>A	4	-				YES	NO
KITc.1675_1677delGTT;c.1678_1680delGTT; c.1679_1681delTTG	3	_				YES	NO
KITc.1669T>C	5	-				YES	NO
KITc.1674_1676AGGT>G	1	_				NO	NO
KITc.1672_1680del9	1	-		~050/	~950/*~700/ /11	YES	NO
KITc.1675_1683del9;c.1676_1684del9;c.167 3_1681delAGGTTGTTG	2	33	27.3%	( mycancergenom	exon)	YES	NO
KITc.2466T>A	2	-		e)	(mycancergenome)	YES	NO
KITc.1694_1717GAAACAATTATGTTTACATAGA CC>CCT	1	-				NO	NO
KITc.1676T>A	4	-				YES	NO
KITc.1676T>G	2	-				YES	NO
KITc.1660_1674del15;c.1661_1675del15	1	_				YES	NO
KITc.1670_1674TGGAAG>ACT	1	_				NO	NO

Supplementary Table 2. Frequencies of point mutations, insertion and delection mutations in 737 loci of 45 genes in 121 GISTs.

KITc.1735_1737delGAT;c.1733_1735delATG 5		-				NO	NO
KITc.1679T>G 2		_				YES	NO
KITc.1727T>C	2	_				YES	NO
KITc.2464A>T	1	_				YES	NO
KITc.1728_1729insCCTTATGATCACAAA	1	_				NO	NO
KITc.1668_1721del54	1	-				YES	NO
KITc.1667_1673CAGTGGAA>CCCAC	1					YES	NO
KITc.1676T>C	1	-				YES	NO
KITc.1669T>A	2	-				YES	NO
KITc.1679_1680TT>AG	1	-				YES	NO
KITc.1669T>G	1	-				YES	NO
KITc.1669_1710del42	1	-				YES	NO
KITc.1653_1676del24	1	-				YES	NO
KITc.1670_1678del9	1	_				YES	NO
KITc.1689_1733del45	1	_				NO	NO
KITc.1670_1675del6	1	-				YES	NO
KITc.2153C>G	1	_				NO	NO
KITc.1673_1693del21	1	-				YES	NO
KITc.1671_1672GA>TG	1	_				NO	NO
KITc.1667_1673>CC	1	_				YES	NO
KRASc.34G>C	1	1	0.8%	~5% <sup>[4]</sup>	-	NO	NO
	1	1	0.8%	~5%(mycancergeno	~5%*~5%(18 exon)	VEC	NO
PDGFKAC.2525A>1		1 		me)	(mycancergenome)	TES	NO

#	Sample ID	Cosmic ID	Gene	CDS change	Amino acid change	Variant frequenc y (%)	Sanger result Consistent
1	13	26085	MLH1	c.1151T>A	p.V384D	66.81	YES
2	95	26085	MLH1	c.1151T>A	p.V384D	46.96	YES
3	25	28026	KIT	c.1621A>C	p.M541L	50.38	YES
4	31		KIT	c.1653_1676del24	p.551del_frames hift	50.89	YES
5	112	1210; 1217	KIT	c.1667_1672del6;c .1669_1674del6	p.W557_K558del	45.39	YES
6	95	1210;1217	KIT	c.1667_1672del6;c .1669_1674del6	p.W557_K558del	35.82	YES
7	76		KIT	c.1670_1674TGGA AG>ACT	p.W557_K558>T	39.18	YES
8	109		KIT	c.1667_1673CAGT GGAA>CCCAC	p.Q556_K558>PT	33.01	YES
9	76		KIT	c.1670_1674TGGA AG>ACT	p.W557_K558>T	39.18	YES
10	25	1221	КІТ	c.1669T>G	p.W557G	36.7	YES
11	27		KIT	c.1674_1676AGGT >G	p.K558_V559>S	86.18	YES
12	101	1240	KIT	c.1673_1693del21	p.558del_frames hift	75.45	YES
13	107	1250;1254	КІТ	c.1675_1683del9;c .1676_1684del9;c. 1673_1681delAGG TTGTTG	p.V559_E561del	48.06	YES
14	106	1252	KIT	c.1676T>A	p.V559D	42.72	YES
15	91	1257	KIT	c.1679T>A	p.V560D	37.31	YES
16	90	1290	KIT	c.1727T>C	p.L576P	51.25	YES
17	107	1290	KIT	c.1727T>C	p.L576P	42.21	YES
18	111	1294;255168	KIT	c.1735_1737delGA T;c.1733_1735delA TG	p.D579del	59.83	YES
19	92	19109	КІТ	c.2464A>T	p.N822Y	27.88	YES
20	49	1321	КІТ	c.2466T>A	p.N822K	27.55	YES
21	106	710	MET	c.1124A>G	p.N375S	50.73	YES

# **Supplementary Table 3. Sanger results**

#### **Sanger figures**

#1



![](_page_8_Figure_3.jpeg)

Ion Torrent

Sanger

![](_page_9_Figure_0.jpeg)

![](_page_9_Figure_1.jpeg)

![](_page_9_Figure_3.jpeg)

Ion Torrent

Sanger

![](_page_9_Figure_6.jpeg)

![](_page_10_Figure_0.jpeg)

![](_page_10_Figure_1.jpeg)

![](_page_10_Figure_2.jpeg)

Ion Torrent

![](_page_10_Figure_4.jpeg)

#9

![](_page_10_Figure_6.jpeg)

![](_page_11_Figure_1.jpeg)

![](_page_11_Figure_2.jpeg)

Ion Torrent

Sanger

#12

![](_page_11_Figure_6.jpeg)

![](_page_12_Figure_1.jpeg)

![](_page_12_Figure_2.jpeg)

Ion Torrent

Sanger

![](_page_12_Figure_5.jpeg)

![](_page_13_Figure_1.jpeg)

![](_page_14_Picture_1.jpeg)

I IT GIT T CTI IT TIT GT Ğ

![](_page_14_Figure_3.jpeg)

Sanger

Ŧ Ŧ Ā Ť

Ion Torrent

#### #20

#21

![](_page_14_Figure_6.jpeg)

Ion Torrent

![](_page_14_Figure_8.jpeg)

G T G G T

![](_page_14_Figure_9.jpeg)

Sanger

![](_page_14_Figure_11.jpeg)

Ē Ā Ť

Ion Torrent

Characteristic		#
Condor	female	59(48.8%)
Gender	male	62(51.2%)
Age	Average 59±11	Median:59, range:24-82
Histology	gastric	76(62.8%)
HISTOIOBA	intestinal	45(37.2%)
	CD117-	3(2.5%)
	CD117+	17(14.0%)
CD117	CD117++	23(19.0%)
	CD117+++	21(17.4%)
	unknown	57(47.1%)
	CD34-	12(9.9%)
	CD34+	20(16.5%)
CD34	CD34++	16(13.2%)
	CD34+++	17(14.0%)
	unknown	56(46.3%)

Supplementary Table 5. Clinical features of 121 GIST patients.